BPC-157 Arginate Oral: Scientific Profile
Publicado el · Actualizado el
Synthetic pentadecapeptide derived from a gastric protein, optimized with an arginate salt to raise gastric stability and bioavailability in research studies on mucosae.
BPC-157 Arginate Oral represents a chemical evolution of the standard BPC-157 pentadecapeptide. Unlike the acetate form, the arginate salt provides superior resistance to the acidic degradation of gastric juice, allowing the compound to maintain its structural integrity and bioactivity during transit through the digestive tract in research models. This peptide is a 15-amino-acid sequence derived from a protective protein originally isolated from human gastric juice.
In laboratory settings, this compound has been documented to act by upregulating vascular endothelial growth factors (VEGF), facilitating angiogenesis and neovascularization processes. These properties are fundamental in the research of soft tissue regeneration, including tendons, ligaments and especially the integrity of the gastric epithelial barrier. It has been observed that its mechanism does not depend on hormonal mediation, but rather on the direct modulation of nitric oxide synthase (NOS).
In addition to its effects on peripheral tissues, current research suggests a neuroprotective role through interaction with the dopaminergic and serotonergic systems. This pharmacological profile positions it as a versatile subject of study in trials that seek to mitigate systemic and chronic inflammatory processes. The oral presentation facilitates constant administration protocols without requiring invasive methods, maintaining stable plasma concentrations in the study subjects.
Mechanism of action
It acts mainly through the activation of the VEGFR2 pathway, promoting the formation of new blood vessels through the expression of EGR-1. It modulates the activity of endothelial nitric oxide synthase (eNOS), which influences the inflammatory response and the protection of the mucosa. Likewise, it influences the expression of genes associated with the repair of the extracellular matrix, such as type I collagen, and regulates the adhesion of fibroblasts in models of tendon injury.
Mechanism summary
It modulates angiogenesis through the VEGF pathway and regulates nitric oxide synthase to promote tissue repair and the integrity of the gastric mucosa.
Estudios Clínicos (10)
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. (Mateescu DM, et al. · Pharmaceutics · 2026) PMID 42198317.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. (Lee E, et al. · Altern Ther Health Med · 2025) PMID 40131143.
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. (Lee E, et al. · Altern Ther Health Med · 2024) PMID 39325560.
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. (Vasireddi N, et al. · HSS J · 2025) PMID 40756949.
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. (He L, et al. · Front Pharmacol · 2022) PMID 36588717.
- Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. (Cerovecki T, et al. · J Orthop Res · 2010) PMID 20225319.
- Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. (Ilic S, et al. · Life Sci · 2011) PMID 21295044.
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. (Mendias CL, et al. · Sports Med · 2026) PMID 41966639.
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang, et al. · Journal of Applied Physiology (1985) · 2011) PMID 21030672.
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs (He, et al. · Frontiers in Pharmacology · 2022)
Warnings
BPC-157 Arginate Oral is a research-use-only (RUO) compound; the following warnings and handling considerations apply to its laboratory use:
- For exclusive use in laboratories and research only
- Its safety has not been evaluated in gestation or lactation models
- Must be handled under strict biosafety protocols
- Presence of active neoplasms or uncontrolled angiogenesis
- Hypersensitivity to the pentadecapeptide BPC-157
- Coagulation disorders documented in the study subject
Technical data
- CAS
- 137525-51-0
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.5 Da
- Compound type
- peptide
- Storage
- -20 °C liofilizado; proteger de la luz; en lugar seco
- Shelf life (lyophilized)
- 24 months
- Shelf life (reconstituted)
- Not applicable (solid oral presentation)
- Light-sensitive
- Sí
Available for research
BPC-157 Arginate Oral is available as a research reagent (RUO):
Frequently asked questions about BPC-157 Arginate Oral
What is BPC-157 Arginate Oral?
Synthetic pentadecapeptide derived from a gastric protein, optimized with an arginate salt to raise gastric stability and bioavailability in research studies on mucosae.
What is the mechanism of action of BPC-157 Arginate Oral?
It modulates angiogenesis through the VEGF pathway and regulates nitric oxide synthase to promote tissue repair and the integrity of the gastric mucosa.
What is BPC-157 Arginate Oral researched for?
In preclinical research, BPC-157 Arginate Oral is studied mainly in: Research on the regeneration of the gastrointestinal mucosa; Modulation of neovascularization in soft tissues; Study of ligament and tendon repair under oral administration. Material exclusively for scientific research.
What are the chemical properties of BPC-157 Arginate Oral?
Molecular formula C62H98N16O22; molecular weight 1419.5 Da; CAS number 137525-51-0.
How is BPC-157 Arginate Oral stored?
Condiciones de conservación: -20 °C liofilizado; proteger de la luz; en lugar seco; estabilidad liofilizado: 24 meses; una vez reconstituido: No aplica (presentación oral sólida); protéjase de la luz.
What routes of administration are studied for BPC-157 Arginate Oral?
In research models the following are described: Oral. Use is exclusively for scientific research.